A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Necitumumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms JFCK
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2016 Results of pooled analysis of venous thromboembolism from this and other trials (SQUIRE, INSPIRE, JFCL) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 20 May 2016 Time frame for primary endpoint has been changed.
    • 02 Mar 2016 Status changed from active, no longer recruiting to completed, as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top